

REVIEWS

Adv Clin Exp Med 2014, 23, 2, 307–311
ISSN 1899–5276

© Copyright by Wrocław Medical University

JAROSŁAW LESZCZYŹYŃ^{1, A, D-F}, IGOR ŁEBSKI^{2, A, B}, LIDIA ŁYSENKO^{3, B, C}, LIDIA HIRNLE^{4, B, C},
HANNA GERBER^{5, B, C}

Anal Warts (*Condylomata Acuminata*) – Current Issues and Treatment Modalities

¹ EMC HC Clinic, Dublin, Republic of Ireland

² EuroMediCare Specialist Hospital, Wrocław, Poland

³ Department of Anesthesiology and Intensive Therapy, Wrocław Medical University, Poland

⁴ Department of Gynecology, Obstetrics and Neonatology, Wrocław Medical University, Poland

⁵ Department of CranioMaxilloFacial Surgery, Wrocław Medical University, Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;
D – writing the article; E – critical revision of the article; F – final approval of article; G – other

Abstract

HPV infections are currently the most frequent cause of genital infections in the USA. Risk factors are early onset of sexual activity, multiple sexual partners, a history STDs, an early age of first pregnancy and tobacco use. In the past, HPV viruses were thought to be STDs, but it is now known that penetration is not necessary. Skin-to-skin or mucosa-to-mucosa contact is enough to transmit the virus, which presents high tropism for those tissues. The *Papillomaviridae* family includes over 120 viruses, some of which have high malignant transformation rates. The most common malignancy connected to HPV is uterine cervix cancer and anal canal cancer. The range of morphology of perianal lesions means that a thorough clinical examination is required, including an anoscopy. Therapeutic modalities often seek to eliminate macroscopic changes rather than focus on the cause of the infection, which leads to a high recurrence rate. Externally located changes can be eliminated with patient-applied treatments. Those located in the anal canal and distal end of the rectal ampulla require treatment by a qualified medical provider. Due to the high recurrence rate after standard treatment, special attention has been given to vaccinations. The polyvalent vaccine includes HPV viruses with both low and high malignant transformation risk. This has led to a decrease in the rate of malignancies (*Adv Clin Exp Med* 2014, 23, 2, 307–311).

Key words: *condylomata acuminata*, anal canal, cryotherapy, electrosurgery, vaccination.

The Epidemiology and Biology of HPV Anal Infections

The Human Papilloma Virus (HPV) used to be thought of as one of the most common sexually transmitted diseases (STDs) [1]. However, penetrative sexual contact is not in fact necessary to transmit the virus, which is predominantly transmitted by skin-to-skin or mucosa-to-mucosa contact [2]. The HPV family (*Papillomaviridae*) consists of more than 120 viruses presenting a tropism towards either the cutaneous or mucosa epithelium. The frequency of HPV infection has risen in the past 35 years, and this can be attributed to

a decrease in the age of the first sexual contact as well as an increase in the number of sex partners [3]. HPV is the most common genital infection in the US, and the lifetime risk of at least one HPV infection in women is 75% [1, 4]. The prevalence of anal HPV infection is very high: about 57% in HIV-negative men who have sex with men (MSM) [5]; and among HIV-positive men the infection rate is about 60 times higher than in the general male population [6]. Several risk factors for HPV infection have been identified: early onset of sexual activity, multiple sexual partners, a history of STDs, an early age of first pregnancy and tobacco use [7].

HPV penetrates skin or mucosa up to the basal membrane in search of keratinocytes (basal

composition as well as general respiratory cytokine responses against *Klebsiella pneumonia* [21].

Imiquimod is applied three times per week for up to 16 weeks. There are many possible local side effects: skin irritation, a burning sensation, pain or skin ulcers. Some patients experience systemic side effects such as headache, muscle ache or fatigue. Unlike the Imiquimod 5% formula, the 3.5% cream has not been known to cause systemic side effects, but there is a substantial difference in the wart clearance rate of the 5% and 3.5% formulations: 56% vs. 36.6%, respectively [18, 22]. The Imiquimod 5% cream has also shown a low recurrence rate of only 13% [18].

Sin catechins (Polypyphenon *E*) 15% ointment is a purified botanical drug isolated from green tea leaves (*Camellia sinensis*). This is actually the first botanical prescription drug that was approved by the FDA [23]. The exact mechanism by which it eradicates anogenital warts has not been fully elucidated. It has been proposed that sin catechins promote the release of cytokine and inhibit cell growth, which is then thought to inhibit transcription factors AP-1 and NF-kappaB [24]. Sin catechins have been shown to modulate apoptosis at various points in the sequence, including altering the expression of anti- and proapoptotic genes. Their anti-inflammatory effects are activated through a variety of different mechanisms, including the modulation of nitric oxide synthase isoforms [25, 26] and the inhibition of several enzymes and kinases involved in generating multiple inflammatory mediators, like proteases and oxygenases [27].

Sin catechins 15% ointment is applied 3 times per week for up to 4 months. The eradication rate is 54.9%, which is similar to other topically applied treatments, and the recurrence rate is 6.5%. The local side effects are also similar to other topical formulations: redness, irritation or a burning sensation, but are reported by only 1 out of 3 treated patients [28].

In conclusion, the available topical treatment options seem to have similar eradication and recurrence rates. The choice of an appropriate treatment should be based on local market availability and price rather than medical or pharmacological factors.

Modalities for Anal Wart Treatment Administered by a Medical Provider

Currently, the Center for Disease Control and Prevention recommendations for specialist-applied treatment of anal warts are 80–90% trichloroacetic

acid (TCA) application, cryotherapy with liquid nitrogen or surgery/electrosurgery [29].

TCA is a potent, erosive and chemically destructive agent that can burn and cauterize skin lesions. Care must be taken during application to avoid staining healthy skin near the anal warts. It is not recommended for intra-anal use. The acid can deeply erode the skin, but the success rates are satisfactory, ranging from 70 to 81% [30, 31]. The reported recurrence rate is high: 36% [31].

Cryotherapy seems to be the best option among the professionally applied techniques. During the treatment, lesions are frozen using a liquid nitrogen cooling probe, which results in necrosis and further clearance of destroyed tissue. Results and complications vary, and can include the destruction of healthy skin, ulcers or scar formation. Cryotherapy is cost effective, minimally invasive, painless and can be applied to intra-anal warts. The eradication rates are similar to TCA: from 81% to 86%, with a recurrence rate of 39% [30, 31].

Surgical excision is the oldest approach, and nowadays seems to be somewhat outdated. However, for patients suffering from a giant condyloma (Buschke-Loewenstein tumor) it may be the treatment of choice [32, 33]. A more contemporary surgical approach, electrosurgery, is a very effective technique with a clearance rate of 94% [34] but can be painful and requires local or intravenous anesthesia.

The specialist-applied modalities are characterized by an eradication rate that ranges from satisfactory to extremely high. However, the high recurrence rate (25–40%) [34] discourages clinical use. The direct-applied modalities that are targeted to remove warts locally do not destroy all the very small or subclinical lesions in the surrounding healthy-looking skin and this may be the cause of recurrence.

Preventive Treatment

In the absence of an ideal treatment for anal warts, prevention could be the best option. The first HPV vaccine (HPV 6, 11, 16, 18) Gardasil was approved by the FDA in 2006 for prophylactic vaccination of girls and young women 9 to 29 years of age [35]. The vaccine is composed of an HPV L1 protein assembled into non-infectious, recombinant virus like particles (VLPs). Gardasil triggers the formation of host antibodies for four HPV subtypes and can provide protection for up to 5 years [36]. The vaccination provides much better protection than a person's natural immunity after an HPV infection. Seroconversion rates were 97.5% or more in multiple studies, compared to a 54% to

69% rate from natural immunity [37]. This quadrivalent vaccine spectrum covers both the high oncogenic risk HPV subtypes (16 and 18) and the low-risk subtypes (6, 11). HPV 16 and 18 are the main pathophysiologic factors that cause uterine cervix cancer and most anal cancers. Furthermore, it has been proven that more than 70% of cervical cancers are caused by those two HPV subtypes [38], while HPV 6 and 11 are etiologic factors in 72% of anal warts [39].

In 2009, the FDA approved the expansion of the therapeutic indications for Gardasil to include boys and young men between 9 and 26 years of

age. Giuliano et al. have reported that the efficacy of Gardasil is 90.4% against external anogenital warts in a group of 4065 healthy males between 16 and 26 years of age [40].

In conclusion, anti-HPV vaccination programs for populations of young women and young men will substantially reduce the incidence of HPV-related diseases: anogenital warts, low-grade cervical dysplasia, cervical cancer, anal cancer and recurrent respiratory papillomatosis (WHO). Widespread HPV vaccination to reduce the viral burden of HPV is critical and necessary to completely eradicate the virus in the population at large.

References

- [1] **Baseman JG, Koutsky LA:** The epidemiology of human papillomavirus infection. *J Clin Virol* 2005, 32, Suppl 1, S16–S24.
- [2] **Vermud SH, Bhatta MP, Sahasrabudde VV:** Papillomavirus infection in *Infectious Diseases* by Cohen J, Powderly WG, Opal SM, Mosby 2010.
- [3] **Weinstock H, Berman S, Cates W Jr:** Sexually transmitted diseases among American youth: incidence and prevalence estimates 2000. *Perspect Sex Reprod Health* 2004, 36, 6–10.
- [4] **Cates W:** Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. *Sex Transm Dis* 1999, 26 (Suppl), S2–S7.
- [5] **Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky M:** Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. *J Infect Dis* 2004, 190, 2070–2076.
- [6] **Frisch M, Biggar RJ, Goedert JJ:** Human papillomavirus associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst* 2000, 92, 1500–1510.
- [7] **Dizon DS, Stuckey AR, Krychman ML:** at Human papilloma virus, Jones & Bartlett Learnig, Sudbury, MA, USA 2012.
- [8] Human papilloma viruses. In *IARC Monographs on the Evaluation of Carcinogenic Risks to Human*, vol90 Lyon, France: International Agency for Research on Cancer 2007, 209–222.
- [9] **Yanofsky VR, Patel RV, Goldenberg G:** Genital warts – A comprehensive review. *J Clin Aesthetic* 2012, 5, 25–36.
- [10] **Sturegard E, Johansson H, Ekstrom J, Hasson BG, Johnsson A, Gustafsson E, Dillner J, Forslund O:** Human papillomavirus typing in reporting condyloma. *Sex Transm Dis* 2013, 40, 123–129.
- [11] **Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J:** A population-based five-year follow-up study of cervical human papillomavirus infection. *Am J Obstet Gynecol* 2000, 183, 561–567.
- [12] **Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott Dr, Rush BB, Glass AG, Schiffman M:** The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) 16 and 18 and the possible utility of type-specific HPV testing in clinical practice. *J Natl Cancer Inst* 2005, 97, 1072–1079.
- [13] **Lee PK, Bas Wilkins K:** Condyloma and other infections including human immunodeficiency virus. *Surg Clin N Am* 2010, 90, 99–112.
- [14] **Kodner CM, Nasraty S:** Management of genital warts. *Am Fam Physican* 2004, 2335–2342.
- [15] **Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW:** Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. *Genitourin Med* 1991, 67, 297–302.
- [16] **Kaplan IW:** Condylomata acuminata. *New Orleans Med Surg J* 1942, 94, 388–90.
- [17] **Lacey CJN, Goodall RL, Rangarson Tennvall G, Maw R, Kinghorn GR, Fisk PG, Barton S, Byren I:** Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. *Sex Transm Infect* 2003, 79, 270–275.
- [18] **Edwards A, Atma-Ram A, Thin RN:** Podophyllotoxin 0.5% v. podophyllin 20% to treat penile warts. *Genitourin Med* 1988, 64, 263–265.
- [19] **Gaspari AA:** Mechanisms of action and other potential roles of an immune response modifier. *Cutis* 2007, 79, Suppl 4, 36–45.
- [20] **Chuang Chi-Mu, Monie A, Hung Chien-fu, Wu T-C:** Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. *J Biomed Sci* 2010, 17, 31–40.
- [21] **Hackenstein H, Hagel N, Knoche A, Kranz S, Lohmeyer J, von Wulffen W, Kershaw O, Gruber AD, Bein G, Baal N:** Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells. *PLoS ONE* 2012, 7, e43430. doi: 10.1371/journal.pone.0043320.

- [22] Baker DA, Ferris DG, Martens MG, Fife KH, Tyring SK, Edwards L, Nelson A, Ault K, Trofatter KE, Liu T, Levy S, Wu J: Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo controlled studies. *Infect Dis Obstet Gyn* 2011, article ID 8061105, 11 pages, doi: 10.1155/2011/806105.
- [23] Meltzer SM, Monk BJ, Tewari KS: Green tea catechins for treatment of external genital warts. *Am J Obstet Gynecol* 2009, 200:233.e1-7. doi: 10.1016/j.ajog.2008.07.064.
- [24] Ahn W-S, Huh S-W, Kim CM, Lim JM, Namkoong SE, Bae SM, Lee IP: Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. *Eur J Cancer Prev* 2003, 12, 383–390.
- [25] Shuterland BA, Rahman RM, Appleton I: Mechanisms of cation of green tea catechins, with a focus on ischemia-induced neurodegeneration. *J Nutr Biochem* 2006, 17, 291–306.
- [26] Tyring SK: Effect of sin catechins on HPV-activated cell growth and induction of apoptosis. *J Clin Aesthet Dermatol* 2012, 5, 34–41.
- [27] Tyring SK: Effects on HPV-induced enzymes involved in inflammatory mediator generation. *J Clin Aesth Dermatol* 2012, 5, 19–26.
- [28] Tatti S, Stockfleth E, Beutner KR, Tawfik K, Elsasser U, Weyrauch P, Mescheder A: Polyphenon E: a new treatment for external anogenital warts. *Br J Dermatol* 2010, 162, 176–184. doi: 10.1111/j.1365-2133.2009.09375.
- [29] CDC-Genital Warts – 2010 STD Treatment Guidelines, www.cdc.gov/std/treatment/2010/genital-warts.htm.
- [30] Abdullah AN, Walzman M, Wade A: Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. *Sex Transm Dis* 1993, 20, 344–345.
- [31] Godley MJ, Bradbeer CS, Gellan M, Thin RN: Cryotherapy compared with trichloroacetic acid in treating genital warts. *Genitourin Med* 1987, 63, 390–392.
- [32] Balik E, Eren T, Bugra D: A surgical approach to anogenital Buschke-Loewenstein tumours (giant condyloma acuminata). *Acta Chir Belgica* 2009, 109, 612–616.
- [33] Paraskevas KI, Kyriakos E, Poullos V, Stathopoulos A, Tzovaras A, Briana DD: Surgical management of giant condyloma acuminatum (Suschke-Loewenstein tumor) of the perianal region. *Dermatol Surg* 2007, 33, 638–644.
- [34] Stone KM, Becker TM, Hagdu A, Kraus SJ: Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. *Genitourin Med* 1990, 66, 16–19.
- [35] Shwarz JL: HPV vaccination's second act: promotion, competition, and compulsion. *Am J Public Health* 2010, 100, 1841–1844.
- [36] Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgrén K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E: Induction of immune memory following administration of prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. *Vaccine* 2007, 25, 4931–4939.
- [37] Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS: Protocol 016 Study Group.: Comparison of immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. *Pediatrics* 2006, 118, 2135–2145.
- [38] Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Eng J Med* 2003, 348, 518–527.
- [39] Sturegard E, Johansson H, Ekstrom J, Hansson BG, Johnsson A, Gustafsson E, Dillner J, Forslund O: Human papillomavirus typing in reporting of condyloma. *Sex Transm Dis* 2013, 40, 123–129.
- [40] Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jenssen H, Hillman R, Chang Y-H, Ferris D, Rouleau D, Bryana J, Marshall B, Vuocolo S, Barr E, Radley D, Haupt R, Guris D: Efficacy of quadrivalent HPV vaccine against HPV infection disease in males. *N Eng J Med* 2011, 364, 401–411.
- [41] Human papilloma vaccines. WHO position paper. *Wkly Epidemiol Rec* 2009, 84, 118–131.

Address for correspondence:

Jarosław Leszczyszyn
EMC HC Clinic
49-51 Parnell Square West
Dublin
Republic of Ireland
Tel.: +48 661 302 302
E-mail: jleszczyszyn@emc-healthcare.ie

Conflict of interest: None declared

Received: 27.02.2013

Revised: 23.10.2013

Accepted: 7.04.2014